- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Leukemias | Clinical
Venugopal Considers BTK and BCL2 Inhibitors in Patient With CLL
July 22, 2021
Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.
Using CAR T-Cell Therapy Earlier May Produce More Benefit in ALL
July 08, 2021
Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.
FDA Approves Rylaze for Subsets of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
July 01, 2021
The FDA has granted approval to Rylaze for use within a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products that are traditionally used.
Early Study of CYNK-001 Expands to Include R/R Acute Myeloid Leukemia Cohort
June 29, 2021
Patients with relapsed/refractory acute myeloid leukemia will now be assesses with the off-the-shelf cell therapy CYNK-001 after a case of conversion to minimal residual disease negativity at its highest dose level.
FDA Grants Fast Track Designation to SNDX-5613 for R/R MLLr and NMP1-Mutant Acute Leukemias
June 28, 2021
The FDA has granted fast track designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias who harbor a mixed lineage leukemia rearranged or nucleophosmin mutation.
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
June 16, 2021
The FDA approved the use of avapritinib for patients with advanced systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.
Long-Term Clinical Benefit Potential Seen with KTE-X19 for Relapsed/Refractory B-ALL
June 04, 2021
A robust and durable response was seen in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia after receiving a single infusion of KTE-X19, a CAR T-cell therapy.
Ponatinib Plus Blinatumomab Shows Potential as a Chemo-Free Option for Ph+ ALL
June 04, 2021
Early results of a phase 2 study show that the efficacy achieved with the combination of ponatinib and blinatumomab represents a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.
FDA Accepts NDA For Pacritinib to Treat Myelofibrosis and Thrombocytopenia
June 01, 2021
The FDA has accepted and granted priority review to a new drug application for pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L.
FDA Accepts BLA for Ublituxumab and Umbralisib for Chronic Lymphocytic Leukemia
May 25, 2021
The FDA has accepted the biologic license application (BLA) for ublituximab in combination with umbralisib for the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.